Last updated 2026-08-22
- Raised Seed round led by GRAM Biotech Venture Foundry Ltd., Jan 2026
Total raised
—
Stage
—
Founded
2026
Headcount
—
HQ
Tel Aviv, Israel
Sector
Biomed
About
Immunexia is focused on developing novel, targeted therapies for sepsis and inflammatory diseases by selectively modulating key immune receptors that drive pathological inflammation. Leveraging engineered blocking peptides, small molecules and nanobodies, the company is building a flexible therapeutic platform that can be adapted across multiple inflammatory indications. Its platform targets an unmet medical need in areas where current treatments are often non-specific, risky or ineffective with the potential for both clinical impact and broad commercial applicability.
Funding history · 1 round · — total
2026-01
Seed
Undisclosed
★ GRAM Biotech Venture Foundry Ltd.
Q&A
- When was Immunexia founded?
- Immunexia was founded in 2026.
- What is Immunexia's primary focus?
- Immunexia is focused on developing novel, targeted therapies for sepsis and inflammatory diseases by selectively modulating key immune receptors that drive pathological inflammation.
- Where is Immunexia headquartered?
- Immunexia is headquartered in Tel Aviv, Israel.
- What type of funding round did Immunexia complete in January 2026?
- In January 2026, Immunexia completed a Seed funding round.
- Which investor participated in Immunexia's Seed round in January 2026?
- GRAM Biotech Venture Foundry Ltd. participated in Immunexia's Seed round in January 2026.
- What technologies does Immunexia leverage for its therapeutic platform?
- Immunexia leverages engineered blocking peptides, small molecules, and nanobodies for its flexible therapeutic platform.
- What is the primary sector of Immunexia?
- Immunexia's primary sector is Biomed.
Sectors & technology
Primary sector
Biomed
Technologies
Target customers
Business model
B2B
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2026 |
|---|